KR101782570B1
(ko)
|
2008-12-09 |
2017-09-27 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
EP3409278B8
(en)
|
2011-07-21 |
2020-11-04 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
EP3770176A1
(en)
|
2013-05-02 |
2021-01-27 |
AnaptysBio, Inc. |
Antibodies directed against programmed death-1 (pd-1)
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
AU2014361473B2
(en)
|
2013-12-12 |
2019-09-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015228372B2
(en)
|
2014-03-12 |
2018-05-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
WO2017042633A2
(en)
*
|
2015-09-10 |
2017-03-16 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
WO2016020856A2
(en)
|
2014-08-05 |
2016-02-11 |
MabQuest SA |
Immunological reagents
|
MX2017003227A
(es)
|
2014-09-13 |
2017-12-04 |
Novartis Ag |
Terapias de combinacion de inhibidores de alk.
|
HUE050831T2
(hu)
|
2014-11-17 |
2021-01-28 |
Regeneron Pharma |
Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
|
EP3984542A1
(en)
*
|
2014-11-20 |
2022-04-20 |
Promega Corporation |
Systems and methods for assessing modulators of immune checkpoints
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US10556952B2
(en)
|
2015-03-30 |
2020-02-11 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to Fc gamma receptors
|
US10836827B2
(en)
|
2015-03-30 |
2020-11-17 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
US11933786B2
(en)
|
2015-03-30 |
2024-03-19 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
CN116327915A
(zh)
*
|
2015-04-03 |
2023-06-27 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
MX2017014822A
(es)
|
2015-05-18 |
2018-04-30 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
MX2018000621A
(es)
|
2015-07-13 |
2018-05-11 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
|
WO2017011831A1
(en)
|
2015-07-16 |
2017-01-19 |
Bioxcel Corporation |
A novel approach for treatment of cancer using immunomodulation
|
TW202417048A
(zh)
|
2015-07-30 |
2024-05-01 |
美商宏觀基因股份有限公司 |
Pd-1結合分子和其使用方法
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EA201890456A1
(ru)
|
2015-08-07 |
2018-07-31 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
|
EA201890468A1
(ru)
|
2015-08-11 |
2018-07-31 |
Уси Байолоджикс (Кайман) Инк. |
Новые антитела против белка pd-1
|
AR105654A1
(es)
*
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
MY195059A
(en)
|
2015-09-23 |
2023-01-05 |
Regeneron Pharma |
Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
|
CA2999756A1
(en)
*
|
2015-09-24 |
2017-03-30 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for reducing metastases
|
EP3355920A4
(en)
*
|
2015-09-29 |
2019-05-15 |
Celgene Corporation |
PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
|
EP3356416B1
(en)
*
|
2015-09-29 |
2021-03-24 |
Shanghai Zhangjiang Biotechnology Co., Ltd |
Pd-1 antibodies and uses thereof
|
IL257110B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Bispecific antibodies specific against pd1 and tim3
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
PE20181044A1
(es)
|
2015-10-02 |
2018-07-03 |
Symphogen As |
Anticuerpos anti-pd-1 y composiciones
|
RU2731202C2
(ru)
|
2015-10-08 |
2020-08-31 |
Макродженикс, Инк. |
Комбинированная терапия для лечения рака
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
KR20180069071A
(ko)
*
|
2015-11-03 |
2018-06-22 |
얀센 바이오테크 인코포레이티드 |
Pd-1 및 tim-3과 특이적으로 결합하는 항체 및 그의 용도
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
CN109152798B
(zh)
|
2015-12-02 |
2022-10-21 |
斯特库比股份有限公司 |
特异于糖基化的pd-1的抗体及其使用方法
|
EP3389714A4
(en)
|
2015-12-14 |
2019-11-13 |
MacroGenics, Inc. |
BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
HUE063377T2
(hu)
*
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
CN105669864B
(zh)
*
|
2015-12-23 |
2018-10-16 |
杭州尚健生物技术有限公司 |
抗人程序性死亡受体1抗体及其制备方法和用途
|
EP3405499A4
(en)
*
|
2016-01-21 |
2020-03-18 |
The Board of Trustees of the Leland Stanford Junior University |
TREATING CANCER WITH COMBINATIONS OF IMMUNE REGULATORS
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
JP7089474B2
(ja)
|
2016-01-22 |
2022-06-22 |
マブクエスト エスエー |
免疫学的試薬
|
JP7438662B2
(ja)
*
|
2016-01-25 |
2024-02-27 |
ジェネンテック, インコーポレイテッド |
T細胞依存性二重特異的抗体をアッセイするための方法
|
BR112018015690A2
(pt)
|
2016-02-17 |
2018-12-26 |
Novartis Ag |
anticorpos tgfbeta 2
|
US10537633B2
(en)
|
2016-03-04 |
2020-01-21 |
Jn Biosciences Llc |
Antibodies to TIGIT
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
US10894823B2
(en)
*
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
KR102364249B1
(ko)
|
2016-03-28 |
2022-02-17 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
항-ryk 항체 및 이의 사용 방법
|
CN109195991B
(zh)
|
2016-03-29 |
2023-10-31 |
斯特库比股份有限公司 |
对糖基化pd-l1特异的双重功能抗体及其使用方法
|
CN109071636A
(zh)
|
2016-03-29 |
2018-12-21 |
斯特库比股份有限公司 |
用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法
|
US11597763B2
(en)
|
2016-05-02 |
2023-03-07 |
Tetragenetics, Inc. |
Anti-Kv1.3 antibodies, and methods of production and use thereof
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
SG11201810454YA
(en)
|
2016-06-02 |
2018-12-28 |
Bristol Myers Squibb Co |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
PL3463457T3
(pl)
|
2016-06-02 |
2023-08-21 |
Bristol-Myers Squibb Company |
Blokada pd-1 niwolumabem w opornym chłoniaku hodgkina
|
KR20190015408A
(ko)
|
2016-06-03 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
|
CN109475634A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
|
EP3464373B1
(en)
|
2016-06-03 |
2021-10-27 |
Bristol-Myers Squibb Company |
Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
|
CN109310762A
(zh)
*
|
2016-06-07 |
2019-02-05 |
宏观基因有限公司 |
联合疗法
|
WO2017214182A1
(en)
*
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
MA45233A
(fr)
|
2016-06-10 |
2019-04-17 |
Regeneron Pharma |
Anticorps anti-gitr et leurs utilisations
|
KR20190017767A
(ko)
*
|
2016-06-10 |
2019-02-20 |
노파르티스 아게 |
C-raf 억제제의 치료적 용도
|
US11472856B2
(en)
|
2016-06-13 |
2022-10-18 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
US11406975B2
(en)
|
2016-07-18 |
2022-08-09 |
President And Fellows Of Harvard College |
Human lymphoid tissue-on-chip
|
JP2019528251A
(ja)
|
2016-07-20 |
2019-10-10 |
エスティーキューブ,インコーポレイテッド |
グリコシル化pd−l1に結合する抗体の組合せを使用するがんの処置および治療の方法
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
US11242376B2
(en)
|
2016-08-02 |
2022-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
WO2018026248A1
(ko)
*
|
2016-08-05 |
2018-02-08 |
주식회사 와이바이오로직스 |
프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
|
UA125395C2
(uk)
*
|
2016-08-05 |
2022-03-02 |
І-Байолоджікс Інк. |
Антитіло проти білка-1 запрограмованої клітинної смерті (pd-1) і його застосування
|
JP7198752B2
(ja)
|
2016-08-09 |
2023-01-04 |
カイマブ・リミテッド |
抗icos抗体
|
WO2018039131A1
(en)
*
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
|
IL265605B2
(en)
|
2016-09-29 |
2024-06-01 |
Beijing Hanmi Pharmaceutical Co Ltd |
Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
JP7258747B2
(ja)
|
2016-10-28 |
2023-04-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗pd-1抗体を用いた尿路上皮癌の処置方法
|
KR20190101364A
(ko)
|
2016-11-01 |
2019-08-30 |
테사로, 인코포레이티드 |
예정 사멸-1(pd-1)에 대한 항체
|
MY195110A
(en)
|
2016-11-02 |
2023-01-10 |
Jounce Therapeutics Inc |
Antibodies to PD-1 and uses Thereof
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
CA3042679A1
(en)
|
2016-11-03 |
2018-05-11 |
Bristol-Myers Squibb Company |
Activatable anti-ctla-4 antibodies and uses thereof
|
AU2017356860A1
(en)
|
2016-11-08 |
2019-05-16 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-PD1 and anti-CTLA4 antibodies
|
US11319378B2
(en)
|
2016-11-18 |
2022-05-03 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
|
JP7178999B2
(ja)
*
|
2016-11-18 |
2022-11-28 |
シムフォゲン・アクティーゼルスカブ |
抗pd-1抗体および組成物
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
BR112019011186A2
(pt)
*
|
2016-12-01 |
2019-10-08 |
Regeneron Pharma |
conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
|
PE20190921A1
(es)
|
2016-12-07 |
2019-06-26 |
Agenus Inc |
Anticuerpos y metodos de su utilizacion
|
CN118853845A
(zh)
|
2016-12-09 |
2024-10-29 |
瑞泽恩制药公司 |
用于对t细胞受体进行测序的系统和方法及其用途
|
JP7122758B2
(ja)
*
|
2016-12-23 |
2022-08-22 |
アールイーエムディー バイオセラピューティクス,インコーポレイテッド |
プログラム死-1(pd-1)に結合する抗体を使用する免疫療法
|
CN106674209B
(zh)
*
|
2016-12-23 |
2020-03-06 |
深圳先进技术研究院 |
程序性死亡受体1基因抑制剂及其制备方法与应用
|
CN108203464B
(zh)
*
|
2016-12-25 |
2021-07-20 |
南京金斯瑞生物科技有限公司 |
高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-1抗体
|
CN108239083B
(zh)
|
2016-12-26 |
2021-08-17 |
阿里根公司 |
芳香烃受体调节剂
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
AU2018206481A1
(en)
|
2017-01-09 |
2019-07-25 |
Tesaro, Inc. |
Methods of treating cancer with anti-PD-1 antibodies
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
WO2018134681A1
(en)
*
|
2017-01-20 |
2018-07-26 |
Sanofi |
Anti-tgf-beta antibodies and their use
|
AR110904A1
(es)
*
|
2017-01-20 |
2019-05-15 |
Sanofi Sa |
ANTICUERPOS ANTI-TGF-b Y SU USO
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
TWI788321B
(zh)
|
2017-01-20 |
2023-01-01 |
美商健臻公司 |
骨靶向抗體
|
EP3571231A4
(en)
|
2017-01-20 |
2020-12-02 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
ANTI-PD-1 ANTIBODIES AND USES THEREOF
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
PL3579874T3
(pl)
|
2017-02-10 |
2022-02-28 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1 h-pirazol-1-ilo)pirymidyn-2-ylo)-1 h-pirazol-4-ol i jego zastosowanie w leczeniu nowotworu złośliwego
|
CN110650974B
(zh)
|
2017-02-10 |
2024-04-19 |
瑞泽恩制药公司 |
用于免疫-pet成像的放射性标记的抗-lag3抗体
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
MA47604A
(fr)
*
|
2017-02-21 |
2020-01-01 |
Regeneron Pharma |
Anticorps anti-pd-1 pour le traitement du cancer du poumon
|
AU2018224094A1
(en)
|
2017-02-24 |
2019-09-19 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
AU2018229278A1
(en)
|
2017-02-28 |
2019-10-17 |
Sanofi |
Therapeutic RNA
|
WO2018162944A1
(en)
*
|
2017-03-04 |
2018-09-13 |
Shenzhen Runshin Bioscience |
Recombinant antibodies to programmed death 1 (pd-1) and uses therefor
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
CN110678482A
(zh)
*
|
2017-03-29 |
2020-01-10 |
细胞基因公司 |
包含pd-1结合蛋白的制剂及其制备方法
|
IL313939A
(en)
|
2017-03-31 |
2024-08-01 |
Bristol Myers Squibb Co |
Anti-PD-1 antibodies for the treatment of tumors in patients with a high tumor mutational burden (TMB)
|
EP3608341A4
(en)
|
2017-04-01 |
2021-01-06 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
HETERODIMER BIS SPECIFIC ANTI-PD-1 / ANTI-HER2 ANTIBODIES WITH NATURAL ANTIBODY STRUCTURE AND PRODUCTION OF IT
|
PL3606946T3
(pl)
*
|
2017-04-03 |
2022-11-28 |
F. Hoffmann-La Roche Ag |
Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
PE20191741A1
(es)
|
2017-04-05 |
2019-12-12 |
Symphogen As |
Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
|
KR102408873B1
(ko)
|
2017-04-05 |
2022-06-15 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
US11603407B2
(en)
*
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
JP2020520985A
(ja)
*
|
2017-05-22 |
2020-07-16 |
オンコイミューン, インコーポレイテッド |
がん療法における免疫関連有害事象の治療のための可溶性cd24の使用方法
|
MX2019013517A
(es)
|
2017-05-24 |
2020-08-17 |
Pandion Operations Inc |
Inmunotolerancia dirigida.
|
AU2018277559A1
(en)
|
2017-05-30 |
2019-10-17 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
|
BR112019020610A2
(pt)
|
2017-05-30 |
2020-04-22 |
Bristol-Myers Squibb Company |
tratamento de tumores positivos para o lag-3
|
CN118356488A
(zh)
|
2017-05-30 |
2024-07-19 |
百时美施贵宝公司 |
包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
EP3630840A1
(en)
|
2017-06-01 |
2020-04-08 |
Bristol-Myers Squibb Company |
Methods of treating a tumor using an anti-pd-1 antibody
|
CA3065516A1
(en)
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Antibodies that specifically bind pd-1 and methods of use
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
CR20190593A
(es)
|
2017-06-22 |
2020-05-10 |
Novartis Ag |
Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20200019865A
(ko)
|
2017-06-22 |
2020-02-25 |
노파르티스 아게 |
암 치료에 사용하기 위한 il-1베타 결합 항체
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
CN110799537B
(zh)
*
|
2017-06-25 |
2023-07-28 |
西雅图免疫公司 |
抗pd-1抗体及其制备和使用方法
|
KR20200022447A
(ko)
|
2017-06-27 |
2020-03-03 |
노파르티스 아게 |
항-tim-3 항체의 투여 요법 및 그의 용도
|
EP3421494A1
(en)
|
2017-06-29 |
2019-01-02 |
Sanofi |
Use of isatuximab in combination with an anti-pd-1 antibody
|
AU2018298039B2
(en)
|
2017-07-06 |
2023-02-02 |
Regeneron Pharmaceuticals, Inc. |
Cell culture process for making a glycoprotein
|
CN111793060B
(zh)
|
2017-07-14 |
2023-06-06 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
EP3655023A1
(en)
|
2017-07-20 |
2020-05-27 |
Novartis AG |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019023148A1
(en)
*
|
2017-07-24 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
ANTI-CD8 ANTIBODIES AND USES THEREOF
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
WO2019023459A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
US11938219B2
(en)
*
|
2017-07-29 |
2024-03-26 |
University Of Southern California |
Synthetic extracellular vesicles for novel therapies
|
US11541103B2
(en)
|
2017-08-03 |
2023-01-03 |
Amgen Inc. |
Interleukin-21 mutein/ anti-PD-1 antibody conjugates
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
CN111051328B
(zh)
|
2017-08-31 |
2023-11-03 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
WO2019046496A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
CA3074647A1
(en)
*
|
2017-09-07 |
2019-03-14 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
KR20200086371A
(ko)
|
2017-09-20 |
2020-07-16 |
리제너론 파마슈티칼스 인코포레이티드 |
패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
|
WO2019074887A1
(en)
|
2017-10-10 |
2019-04-18 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
WO2019075468A1
(en)
|
2017-10-15 |
2019-04-18 |
Bristol-Myers Squibb Company |
TUMOR TREATMENT METHODS
|
CN111406063B
(zh)
|
2017-10-16 |
2023-09-15 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
KR20200074993A
(ko)
*
|
2017-11-03 |
2020-06-25 |
노파르티스 아게 |
쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
|
WO2019090330A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20200282010A1
(en)
*
|
2017-11-08 |
2020-09-10 |
Epiaxis Therapeutics Pty Ltd |
Immunogenic compositions and uses therefor
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
EP3713937A2
(en)
|
2017-11-20 |
2020-09-30 |
Ariagen, Inc. |
Indole compounds as aryl hydrocarbon receptor (ahr) modulators
|
WO2019108900A1
(en)
|
2017-11-30 |
2019-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
CN109912577B
(zh)
*
|
2017-12-12 |
2021-10-22 |
深圳先进技术研究院 |
用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
JP7321159B2
(ja)
|
2017-12-22 |
2023-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
薬剤生成物不純物を特性決定するためのシステム及び方法
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
UY38049A
(es)
|
2018-01-12 |
2019-07-31 |
Amgen Inc |
Anti-pd-1 anticuerpos y métodos de tratamiento
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
AU2019210332A1
(en)
|
2018-01-22 |
2020-09-10 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
EP3743076A1
(en)
|
2018-01-22 |
2020-12-02 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
CA3085177A1
(en)
|
2018-01-31 |
2019-08-08 |
Regeneron Pharamaceuticals, Inc. |
System and method for characterizing size and charge variant drug product impurities
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
KR102171766B1
(ko)
*
|
2018-02-02 |
2020-10-29 |
주식회사 뉴라클제네틱스 |
Pd-l1 결합력이 증대된 pd-1 변이체
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
GB201802573D0
(en)
*
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
CN111565738B
(zh)
|
2018-02-28 |
2023-12-26 |
圆祥生技股份有限公司 |
结合检查点阻碍物作为目标治疗的双功能性蛋白质
|
MX2020008988A
(es)
|
2018-02-28 |
2020-09-28 |
Regeneron Pharma |
Sistemas y metodos para la identificacion de contaminantes virales.
|
CN111801341B
(zh)
|
2018-03-08 |
2023-10-24 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
JP7315565B2
(ja)
|
2018-03-19 |
2023-07-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
マイクロチップキャピラリー電気泳動アッセイおよび試薬
|
CA3093186A1
(en)
*
|
2018-03-22 |
2019-09-26 |
Keires Ag |
Antagonistic antigen binding proteins
|
US20210040134A1
(en)
*
|
2018-03-23 |
2021-02-11 |
ISR Immune System Regulation Holding AB (publ) |
Combinations of macrolide compounds and immune checkpoint inhibitors
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
CN108546297B
(zh)
*
|
2018-03-29 |
2019-08-02 |
中国人民解放军军事科学院军事医学研究院 |
针对pd-1的单克隆抗体及其应用
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
CN109336975B
(zh)
*
|
2018-04-18 |
2022-05-13 |
中国科学院微生物研究所 |
一种靶向pd-1的肿瘤抑制性抗体及其应用
|
US12037344B2
(en)
|
2018-04-25 |
2024-07-16 |
Innate Tumor Immunity, Inc |
NLRP3 modulators
|
CN110404066B
(zh)
*
|
2018-04-28 |
2022-06-17 |
齐鲁制药有限公司 |
一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
|
CN108840932B
(zh)
*
|
2018-04-28 |
2022-03-29 |
中国科学院微生物研究所 |
一种pd-1特异性抗体及其抗肿瘤应用
|
SG11202010423VA
(en)
|
2018-05-04 |
2020-11-27 |
Merck Patent Gmbh |
COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
CA3100253A1
(en)
|
2018-05-14 |
2019-11-21 |
Immunocore Limited |
Bifunctional binding polypeptides
|
US11136394B2
(en)
|
2018-05-17 |
2021-10-05 |
Nanjing Leads Biolabs Co., Ltd. |
Antibody binding PD-1 and use thereof
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019232319A1
(en)
|
2018-05-31 |
2019-12-05 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting cd73
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
JP2021527431A
(ja)
|
2018-06-21 |
2021-10-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
二重特異性抗psma×抗cd28抗体およびその使用
|
TW202005985A
(zh)
*
|
2018-06-21 |
2020-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
BR112020026384A2
(pt)
|
2018-06-23 |
2021-03-30 |
Genentech, Inc. |
Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
|
US11795206B2
(en)
*
|
2018-06-24 |
2023-10-24 |
Yunbiao Lu |
Specific bifunctional BY-001 (active composition of homomultimer of chimeric protein pd-L1 / fc-gamma1) down regulates the activation of human immune cells and the use thereof
|
JP2021529556A
(ja)
|
2018-06-29 |
2021-11-04 |
ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. |
抗腫瘍アンタゴニスト
|
KR20210042909A
(ko)
*
|
2018-07-09 |
2021-04-20 |
프레시전 인코포레이티드 |
융합 구조물 및 그의 이용 방법
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
HUE063715T2
(hu)
|
2018-07-10 |
2024-01-28 |
Novartis Ag |
3-(5-hidroxi-1-oxoizoindolin-2-il)piperidin-2,6-dion származékok és alkalmazásuk ikaros család cinkujj-2 (IKZF2)-függõ betegségek kezelésében
|
EP3823611A1
(en)
|
2018-07-18 |
2021-05-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
CN112424231B
(zh)
*
|
2018-07-19 |
2022-09-13 |
大有华夏生物医药集团有限公司 |
抗pd-1抗体及其剂量和用途
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
BR112021000511A2
(pt)
|
2018-07-26 |
2021-04-06 |
Bristol-Myers Squibb Company |
Terapia de combinação de lag-3 para o tratamento de câncer
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
KR20210046023A
(ko)
|
2018-08-16 |
2021-04-27 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
KR20210045430A
(ko)
|
2018-08-16 |
2021-04-26 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
CA3109778A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
WO2020041655A1
(en)
|
2018-08-24 |
2020-02-27 |
Sanofi |
Therapeutic rna for solid tumor cancers
|
CN112955221A
(zh)
|
2018-08-27 |
2021-06-11 |
皮里斯制药有限公司 |
包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途
|
MX2021002279A
(es)
|
2018-08-27 |
2021-05-27 |
Regeneron Pharma |
Uso de espectroscopia raman en la purificacion corriente abajo.
|
CA3100038A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
MX2021002190A
(es)
|
2018-08-31 |
2021-05-14 |
Regeneron Pharma |
Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
US20210395392A1
(en)
|
2018-10-09 |
2021-12-23 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
WO2020079581A1
(en)
|
2018-10-16 |
2020-04-23 |
Novartis Ag |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
PL3866850T3
(pl)
|
2018-10-19 |
2024-10-14 |
Bristol-Myers Squibb Company |
Terapia skojarzona czerniaka
|
KR20210081384A
(ko)
|
2018-10-23 |
2021-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
US20210403557A1
(en)
*
|
2018-11-05 |
2021-12-30 |
Merck Sharp & Dohme Corp. |
Dosing regimen of anti-tigit antibody for treatment of cancer
|
EP3880716A4
(en)
|
2018-11-13 |
2022-08-03 |
Compass Therapeutics LLC |
MULTISPECIFIC BINDING CONSTRUCTS DIRECTED AGAINST CHECKPOINT MOLECULES AND ASSOCIATED USES
|
US20210388091A1
(en)
|
2018-11-14 |
2021-12-16 |
Regeneron Pharmaceuticals, Inc. |
Intralesional administration of pd-1 inhibitors for treating skin cancer
|
SG11202104969RA
(en)
|
2018-11-16 |
2021-06-29 |
Bristol Myers Squibb Co |
Anti-nkg2a antibodies and uses thereof
|
TW202038943A
(zh)
|
2018-11-19 |
2020-11-01 |
美商雅里俊公司 |
治療癌症之方法
|
AU2019385497A1
(en)
|
2018-11-20 |
2021-06-17 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
BR112021011224A2
(pt)
|
2018-12-11 |
2021-08-24 |
Theravance Biopharma R&D Ip, Llc |
Inibidores de alk5
|
SG11202105948TA
(en)
|
2018-12-19 |
2021-07-29 |
Regeneron Pharma |
Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
|
MA54540A
(fr)
|
2018-12-19 |
2021-10-27 |
Regeneron Pharma |
Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
|
WO2020132091A2
(en)
*
|
2018-12-19 |
2020-06-25 |
Humabs Biomed Sa |
Antibodies that neutralize hepatitis b virus and uses thereof
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
MX2021007488A
(es)
|
2018-12-21 |
2021-08-05 |
Novartis Ag |
Uso de anticuerpos il-1 beta en el tratamiento o prevencion del sindrome mielodisplasico.
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
US20220054524A1
(en)
|
2018-12-21 |
2022-02-24 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
EP3898674A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
WO2020136133A1
(en)
|
2018-12-23 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Tumor classification based on predicted tumor mutational burden
|
SG11202106765XA
(en)
*
|
2018-12-27 |
2021-07-29 |
Gigagen Inc |
Anti-pd-1 binding proteins and methods of use thereof
|
WO2020150116A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
EP3911641A1
(en)
|
2019-01-14 |
2021-11-24 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
CA3124837A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
KR20210114456A
(ko)
|
2019-01-14 |
2021-09-23 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
암의 치료에 사용하기 위한 nlrp3-조정제로서의 치환된 퀴나졸린
|
WO2020150114A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators, for use in the treatment of cancer
|
EP4220173A3
(en)
|
2019-01-16 |
2023-10-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
KR20210118870A
(ko)
|
2019-01-21 |
2021-10-01 |
사노피 |
진행성 단계의 고형 종양 암에 대한 치료용 rna 및 항-pd1 항체
|
CN113924317A
(zh)
|
2019-02-01 |
2022-01-11 |
葛兰素史克知识产权开发有限公司 |
贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症
|
MX2021009562A
(es)
|
2019-02-12 |
2021-09-08 |
Novartis Ag |
Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
JP7488826B2
(ja)
|
2019-02-15 |
2024-05-22 |
ノバルティス アーゲー |
置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
MA55084A
(fr)
*
|
2019-02-28 |
2022-01-05 |
Regeneron Pharma |
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
|
CA3129963A1
(en)
|
2019-03-06 |
2020-09-10 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
JP7547360B2
(ja)
|
2019-03-22 |
2024-09-09 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
EP3941941A1
(en)
|
2019-03-22 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Egfr x cd28 multispecific antibodies
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
US20220195046A1
(en)
|
2019-03-28 |
2022-06-23 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
CA3134080A1
(en)
|
2019-04-12 |
2020-10-15 |
Vascular Biogenics Ltd. |
Methods of anti-tumor therapy
|
KR20210151951A
(ko)
|
2019-04-15 |
2021-12-14 |
아리아젠, 인크. |
키랄 인돌 화합물 및 그 용도
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
MX2021013519A
(es)
|
2019-05-13 |
2021-12-10 |
Regeneron Pharma |
Ensayos de union de ligandos competitivos mejorados.
|
AU2020276242A1
(en)
|
2019-05-13 |
2021-12-02 |
Regeneron Pharmaceuticals, Inc. |
Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
|
US12012374B2
(en)
|
2019-05-13 |
2024-06-18 |
Bristol-Myers Squibb Company |
Agonists of ROR GAMMAt
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
JP2022533702A
(ja)
|
2019-05-20 |
2022-07-25 |
パンディオン・オペレーションズ・インコーポレイテッド |
MAdCAM標的化免疫寛容
|
WO2020239558A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
KR20220016157A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 조합 요법
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
US20220275088A1
(en)
*
|
2019-06-14 |
2022-09-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-1 and methods of use thereof
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
MA56523A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1
|
JP2022540571A
(ja)
|
2019-06-28 |
2022-09-16 |
ゲンスン バイオファーマ、インコーポレーテッド |
変異したTGFβ1-RII細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Pd−1/cd3二重特異性タンパク質による血液がん治療
|
CA3143478A1
(en)
*
|
2019-07-09 |
2021-01-14 |
Tomer Hertz |
Antibodies with reduced immunogenicity
|
WO2021021991A1
(en)
*
|
2019-08-01 |
2021-02-04 |
Vaccinex,Inc. |
Combined inhibition of semaphorin-4d and tgfb and compositions therefor
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
EP4011918A4
(en)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
DUAL SPECIFIC PROTEIN
|
US11629190B2
(en)
|
2019-08-15 |
2023-04-18 |
Oregon State University |
Canine antibody therapeutic for treating cancer
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
MX2022003197A
(es)
|
2019-09-22 |
2022-04-11 |
Bristol Myers Squibb Co |
Perfilado espacial cuantitativo para terapia con antagonistas de la proteina del gen de activacion de linfocitos 3 (lag-3).
|
WO2021061790A1
(en)
|
2019-09-24 |
2021-04-01 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
MX2022003357A
(es)
|
2019-09-25 |
2022-05-03 |
Seagen Inc |
Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
|
AU2020353079A1
(en)
|
2019-09-25 |
2022-04-14 |
Bristol-Myers Squibb Company |
Composite biomarker for cancer therapy
|
EP4048281A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Combination therapies with venetoclax and tim-3 inhibitors
|
AU2020370832A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
TIM-3 inhibitors and uses thereof
|
CN114846135A
(zh)
|
2019-11-04 |
2022-08-02 |
杜克大学 |
原发性和转移性癌症的治疗
|
MX2022005345A
(es)
*
|
2019-11-04 |
2022-08-11 |
Inovio Pharmaceuticals Inc |
Terapia de combinación para el tratamiento de cáncer cerebral.
|
US20220390455A1
(en)
|
2019-11-05 |
2022-12-08 |
Bristol-Myers Squibb Company |
M-protein assays and uses thereof
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
EP4055609A1
(en)
|
2019-11-07 |
2022-09-14 |
Oncxerna Therapeutics, Inc. |
Classification of tumor microenvironments
|
JP2022553851A
(ja)
|
2019-11-08 |
2022-12-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
黒色腫の処置のためのlag-3アンタゴニスト
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
CN114728941A
(zh)
|
2019-11-22 |
2022-07-08 |
施万生物制药研发Ip有限责任公司 |
作为alk5抑制剂的经取代的1,5-萘啶或喹啉
|
EP4065086A1
(en)
|
2019-11-25 |
2022-10-05 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
AU2020399976A1
(en)
|
2019-12-09 |
2022-06-30 |
Merck Sharp & Dohme B.V. |
Combination therapy with LIV1-ADC and PD-1 antagonist
|
WO2021127554A1
(en)
|
2019-12-19 |
2021-06-24 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
WO2021121373A1
(zh)
*
|
2019-12-20 |
2021-06-24 |
广东菲鹏制药股份有限公司 |
抗人程序死亡因子-1单克隆抗体
|
CA3165399A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
WO2021142203A1
(en)
|
2020-01-10 |
2021-07-15 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
CN115398236B
(zh)
|
2020-01-21 |
2024-06-11 |
瑞泽恩制药公司 |
用于糖基化的蛋白质的电泳的去糖基化方法
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
KR20220133996A
(ko)
|
2020-01-30 |
2022-10-05 |
오엔에이 테라퓨틱스 에스.엘. |
암 및 암 전이를 치료하기 위한 병용 요법
|
CN116650628A
(zh)
|
2020-01-31 |
2023-08-29 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
CN113244385A
(zh)
*
|
2020-02-07 |
2021-08-13 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗恶性肿瘤中的用途
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
WO2021171260A2
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor
|
IL296564A
(en)
|
2020-03-06 |
2022-11-01 |
Celgene Quanticel Res Inc |
A combination of lsd-1 inhibitor and nivolumab for use in the treatment of sclc or sqnsclc
|
US20230235073A1
(en)
|
2020-03-06 |
2023-07-27 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
EP4114859A1
(en)
|
2020-03-06 |
2023-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-gitr antibodies and uses thereof
|
PE20230821A1
(es)
|
2020-03-23 |
2023-05-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-ccr8 para el tratamiento del cancer
|
WO2021195415A1
(en)
*
|
2020-03-26 |
2021-09-30 |
Cureimmune Therapeutics Inc. |
Anti-pd-1 antibodies and methods of use
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
CN115443269A
(zh)
|
2020-03-31 |
2022-12-06 |
施万生物制药研发Ip有限责任公司 |
经取代的嘧啶和使用方法
|
BR112022021105A2
(pt)
|
2020-04-21 |
2022-11-29 |
Novartis Ag |
Regime de dosagem para tratar uma doença modulada por csf-1r
|
KR20230004682A
(ko)
|
2020-04-22 |
2023-01-06 |
머크 샤프 앤드 돔 엘엘씨 |
인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
|
EP4157464A1
(en)
*
|
2020-05-26 |
2023-04-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
|
US20230203157A1
(en)
*
|
2020-05-27 |
2023-06-29 |
Dana-Farber Cancer Institute, Inc. |
Bispecific molecules for selectively modulating t cells
|
PE20231078A1
(es)
|
2020-06-02 |
2023-07-17 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
CN116323607A
(zh)
|
2020-06-10 |
2023-06-23 |
施万生物制药研发Ip有限责任公司 |
用作alk5抑制剂的萘啶衍生物
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
JP2023531537A
(ja)
|
2020-06-30 |
2023-07-24 |
メンドゥス・ベスローテン・フェンノートシャップ |
卵巣癌ワクチンでの白血病由来細胞の使用
|
KR20230035576A
(ko)
|
2020-07-07 |
2023-03-14 |
비온테크 에스이 |
Hpv 양성 암 치료용 rna
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
WO2022046833A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer by administering a pd-1 inhibitor
|
WO2022047189A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
MX2023002326A
(es)
|
2020-08-31 |
2023-03-21 |
Bristol Myers Squibb Co |
Firma de localizacion celular e inmunoterapia.
|
JP2023542820A
(ja)
|
2020-08-31 |
2023-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP7571348B2
(ja)
*
|
2020-08-31 |
2024-10-23 |
ビオシオン インコーポレイテッド |
Pd-1結合抗体及びその用途
|
AU2021337223A1
(en)
|
2020-09-02 |
2023-03-16 |
Msd International Gmbh |
Combination therapy of a PD-1 antagonist and an antagonist for VEGFR-2 for treating patients with cancer
|
IL300975A
(en)
|
2020-09-03 |
2023-04-01 |
Regeneron Pharma |
Methods for treating cancer pain by administering a PD-1 inhibitor
|
CN116348137A
(zh)
|
2020-09-14 |
2023-06-27 |
勃林格殷格翰国际有限公司 |
异源初免加强疫苗
|
IL301037A
(en)
|
2020-09-18 |
2023-05-01 |
Regeneron Pharma |
Antigen binding molecules that bind CD38 and/or CD28 and uses thereof
|
IL301533A
(en)
|
2020-09-24 |
2023-05-01 |
Merck Sharp ַ& Dohme Llc |
Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
|
WO2022072762A1
(en)
|
2020-10-02 |
2022-04-07 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
EP4225770A1
(en)
|
2020-10-05 |
2023-08-16 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
JP2023548051A
(ja)
|
2020-10-23 |
2023-11-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
肺がんのためのlag-3アンタゴニスト療法
|
CA3196535A1
(en)
|
2020-10-28 |
2022-05-05 |
Alfredo C. Castro |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AU2021374592A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
TW202432189A
(zh)
|
2020-11-04 |
2024-08-16 |
美商建南德克公司 |
以抗 cd20/抗 cd3 雙特異性抗體和抗 cd79b 抗體藥物結合物治療的給藥方法
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
EP4243852A1
(en)
*
|
2020-11-13 |
2023-09-20 |
Ludwig Institute for Cancer Research Ltd |
Pd-1 decoy variants for immunotherapy
|
CA3191141A1
(en)
|
2020-11-25 |
2022-06-02 |
Hunter Chen |
Sustained release formulations using non-aqueous membrane emulsification
|
US20220168293A1
(en)
|
2020-12-02 |
2022-06-02 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
KR20230117162A9
(ko)
|
2020-12-02 |
2024-03-21 |
제넨테크, 인크. |
신보조 및 보조 요로상피 암종 요법을 위한 방법 및 조성물
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN116940592A
(zh)
*
|
2020-12-15 |
2023-10-24 |
比卡拉治疗股份有限公司 |
用于治疗癌症的组合疗法
|
US20220257707A1
(en)
|
2020-12-17 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
EP4267172A1
(en)
|
2020-12-28 |
2023-11-01 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
EP4267105A1
(en)
|
2020-12-28 |
2023-11-01 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
AU2022211682A1
(en)
|
2021-01-22 |
2023-08-03 |
Mendus B.V. |
Methods of tumor vaccination
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
MX2023009279A
(es)
|
2021-02-11 |
2023-10-02 |
Regeneron Pharma |
Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
|
BR112023017442A2
(pt)
|
2021-03-03 |
2023-09-26 |
Regeneron Pharma |
Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
|
US20220305100A1
(en)
|
2021-03-12 |
2022-09-29 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
KR20230159590A
(ko)
|
2021-03-23 |
2023-11-21 |
리제너론 파아마슈티컬스, 인크. |
Pd-1 억제제를 투여함에 의한 면역억제 또는 면역손상된 환자에서 암을 치료하는 방법
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
JP2024511166A
(ja)
*
|
2021-03-25 |
2024-03-12 |
オンクセルナ セラピューティクス,インコーポレイテッド |
癌の標的療法
|
MX2023010794A
(es)
|
2021-03-26 |
2023-10-25 |
Regeneron Pharma |
Metodos y sistemas para el desarrollo de protocolos de mezcla.
|
JP2024514245A
(ja)
|
2021-03-29 |
2024-03-29 |
ジュノー セラピューティクス インコーポレイテッド |
チェックポイント阻害剤療法とcar t細胞療法との組合せを用いた投薬および処置のための方法
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022221227A1
(en)
|
2021-04-13 |
2022-10-20 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
EP4330436A1
(en)
|
2021-04-30 |
2024-03-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CA3218786A1
(en)
|
2021-05-25 |
2022-12-01 |
Lifei HOU |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
TW202313117A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
TW202317623A
(zh)
*
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
WO2022266510A1
(en)
|
2021-06-18 |
2022-12-22 |
Genzyme Corporation |
Anti-tgf-beta antibody formulations and their use
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
IL309831A
(en)
|
2021-07-13 |
2024-02-01 |
BioNTech SE |
Multispecific binding agents against CD40 and CD137 in combined cancer therapy
|
IL310201A
(en)
|
2021-07-19 |
2024-03-01 |
Regeneron Pharma |
Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment
|
TW202321282A
(zh)
|
2021-07-19 |
2023-06-01 |
美商再生元醫藥公司 |
Il12受體促效劑及其使用方法
|
MX2024001214A
(es)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Metodos y composiciones para tratar cancer.
|
TW202320848A
(zh)
|
2021-07-28 |
2023-06-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
WO2023007472A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
TW202322846A
(zh)
|
2021-08-16 |
2023-06-16 |
美商再生元醫藥公司 |
新穎的il27受體促效劑及其使用方法
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
EP4405390A1
(en)
|
2021-09-20 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
CA3234647A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
EP4413364A2
(en)
|
2021-10-07 |
2024-08-14 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
CA3230985A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Ph meter calibration and correction
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
EP4423018A1
(en)
|
2021-10-26 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
EP4423133A1
(en)
|
2021-10-29 |
2024-09-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
AU2022384793A1
(en)
|
2021-11-12 |
2024-04-11 |
Advanced Accelerator Applications |
Combination therapy for treating lung cancer
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
EP4436957A1
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
CN116333118B
(zh)
*
|
2021-12-16 |
2024-04-19 |
徕特康(苏州)生物制药有限公司 |
抗表皮生长因子受体抗体及其制备方法和用途
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023133280A1
(en)
|
2022-01-07 |
2023-07-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
MX2024008831A
(es)
|
2022-01-26 |
2024-07-25 |
Bristol Myers Squibb Co |
Terapia combinada para carcinoma hepatocelular.
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
IL314851A
(en)
|
2022-02-17 |
2024-10-01 |
Regeneron Pharma |
Combinations of checkpoint inhibitors and oncolytic virus for cancer treatment
|
MX2024010310A
(es)
|
2022-02-25 |
2024-08-28 |
Bristol Myers Squibb Co |
Terapia de combinacion para carcinoma colorrectal.
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
AU2023230110A1
(en)
|
2022-03-08 |
2024-10-24 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023177772A1
(en)
|
2022-03-17 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
CN118871451A
(zh)
|
2022-03-18 |
2024-10-29 |
百时美施贵宝公司 |
分离多肽的方法
|
US20230296559A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
CN116925223A
(zh)
*
|
2022-04-02 |
2023-10-24 |
普米斯生物技术(珠海)有限公司 |
抗pd-1单克隆抗体及其衍生物和用途
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US20230326022A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023224912A1
(en)
|
2022-05-16 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
US20230391844A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
WO2024018069A1
(en)
|
2022-07-22 |
2024-01-25 |
Philogen S.P.A |
Anti-cd28 antibodies
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
WO2024030453A1
(en)
|
2022-08-02 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
WO2024040229A2
(en)
*
|
2022-08-19 |
2024-02-22 |
Flagship Pioneering Innovations V, Inc. |
Combination therapies comprising myc modulators and checkpoint inhibitors
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
WO2024076926A1
(en)
|
2022-10-03 |
2024-04-11 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
US20240165257A1
(en)
|
2022-11-01 |
2024-05-23 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
WO2024116140A1
(en)
|
2022-12-01 |
2024-06-06 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
WO2024137589A2
(en)
|
2022-12-20 |
2024-06-27 |
Genentech, Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2024137776A1
(en)
|
2022-12-21 |
2024-06-27 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
TW202430560A
(zh)
|
2023-01-06 |
2024-08-01 |
美商拉森醫療公司 |
抗il-18bp抗體
|
WO2024148243A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
WO2024151978A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
US20240248097A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
WO2024160721A1
(en)
|
2023-01-30 |
2024-08-08 |
Kymab Limited |
Antibodies
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
WO2024165403A1
(en)
|
2023-02-06 |
2024-08-15 |
Philogen S.P.A. |
Anti-cea antibodies
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
WO2024175699A1
(en)
|
2023-02-23 |
2024-08-29 |
Imcheck Therapeutics |
Combination of btn3a activating antibody and immune checkpoint inhibitors
|
US20240287186A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
WO2024192033A1
(en)
|
2023-03-13 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
WO2024223299A2
(en)
|
2023-04-26 |
2024-10-31 |
Isa Pharmaceuticals B.V. |
Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
|